All In MedTech

FDA Clearance Tracker · P180002-S019

Zephyr Endobronchial Valve (Zephyr Valve)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 13, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 13, 2021

Approved

Time to decision

28 days

Received Jul 16, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P180002-S019
Device name
Zephyr Endobronchial Valve (Zephyr Valve)
Applicant location
Redwood City, CA
Received
Jul 16, 2021
Decided
Aug 13, 2021
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P180002

Device type

Device class
Class III

Every decision under product code NJK

FDA's approval statement

As written in FDA's record.

Approval for modifications to the protocol to include collection of perfusion data at baseline, extension of high-resolution computed tomography (HRCT) baseline data collection window from 3 months to 6 months prior to Informed Consent date, and collection of HRCT data at 12 months.

Source documents

Other decisions for Pulmonx Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.